Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5417 - 5424 of 12025 results
Discoverability of Third Party Funding Agreements in Arbitration – Part I
January 29, 2019| Blog| Viewpoint
California AG’s Office Gets Public Input on CCPA
January 29, 2019| Blog| Viewpoint
Part D Payment Modernization Model Aimed at Reducing Medicare's Catastrophic Phase Spending
January 28, 2019| Blog| Viewpoint
Vice Chair of Covington & Burling Funds Practice Jumps to Mintz
January 28, 2019| News
The Shutdown Is Over, But Merger Review Backlog Remains
January 28, 2019| News
Commentary: Enact automatic voter registration in N.Y.
January 27, 2019| News
CMS Addresses Drug Manufacturer Coupons in Proposed 2020 Payment Notice
January 25, 2019| Blog| Viewpoint
Unilateral Recalls: Companies Should Consider Launching Recalls Without the CPSC During the Government Shutdown
January 24, 2019| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
The Evolving Global Digital Infrastructure: Data Centers, AI, and the Next Wave of Connectivity
New York, NY
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|